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Emicizumab,	a	bispecific	antibody	mimicking	the	action	of	 factor	VIII	 (FVIII),	 is	cur-
rently the first and only approved and increasingly accessible disruptive treatment 
option	 for	hemophilia	A,	a	disease	so	 far	mainly	 treated	with	 frequent	 intravenous	
infusions	of	FVIII	concentrates	or	bypassing	agents	in	case	of	inhibitor	development.	
Other	disruptive	 treatments	 are	expected	 to	 follow,	 such	as	 agents	 that	 rebalance	
coagulation and gene therapy with the ambition of curing hemophilia. While these 
treatment	options	represent	major	achievements	or	expectations,	their	adoption	and	
implementation	should	consider	their	multiple	direct	and	indirect,	immediate	or	de-
layed,	 consequences	on	hemophilia	 care	globally.	 It	 is	 these	multiple	changes,	pre-
sent	and	future,	already	visible	or	hypothetical,	that	this	article	intends	to	review	and	
explore.




• Emicizumab represents a disruptive treatment of hemophilia.
•	 Beyond	its	mode	of	action	and	route	of	delivery,	its	adoption	and	implementation	could	impact	on	many	aspects	of	hemophilia	care.
•	 These	multiple	changes,	present	or	future,	already	visible	or	hypothetical,	are	reviewed	and	explored.
1  |  INTRODUC TION
A	disruptive	technology	is	a	new	emerging	technology	that	replaces	
the established one. Many disruptive technologies are regularly re-
shaping our societies and the way we live. Examples include what 
email has done for personal communications or what the mobile 
phone has done for the telecommunications industry.1
These technologies are also relevant to hemophilia. Beyond the 
classic substitutive treatment by intravenous administration of fac-
tor	VIII	 (FVIII)	 concentrates,	markedly	 improved	over	 the	past	de-
cades,	a	revolutionary	alternative	has	recently	become	available.2-	5 
This	 is	 the	 bispecific	 antibody	 (emicizumab),	 administered	 subcu-
taneously,	which	mimics	the	hemostatic	action	of	FVIII	without	its	
immunogenicity and lability.6	 Emicizumab,	 however,	 only	 partially	
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corrects	the	FVIII	deficiency	typical	of	severe	hemophilia	A,	so	that	
coadministration	of	FVIII	is	required	in	certain	circumstances.7
Emicizumab represents a disruptive technology that can change 








human	plasma	 and	more	 recently	 using	 recombinant	DNA	 technol-
ogy.2,8	Regardless	of	 the	source,	FVIII	 treatment	suffers	 from	three	
issues	 inherent	to	 its	characteristics:	 (i)	the	need	to	administer	FVIII	
intravenously,	 (ii)	 its	 short	 half-	life,	 and	 (iii)	 its	 immunogenicity.9 




a	 lot	 of	 interindividual	 variability,	 alternating	 concentration	 peaks	
just	after	 infusion,	and	troughs	before	the	next	 infusion.	 In	addition	
to	 these	 challenges,	 FVIII	 is	 particularly	 immunogenic,	 resulting	 in	
the	development	of	neutralizing	antibodies	(inhibitors)	in	a	significant	
proportion	of	mainly	severely	affected	patients,	especially	when	re-
placement therapy is initiated early in life. The development of these 




Emicizumab represents the first approved and widely available 
nonsubstitutive	 therapy	 for	 hemophilia.	 Taking	 advantage	 of	 the	
cofactor	 function	 of	 FVIII	 in	 coagulation,	 this	 bispecific	 antibody	
binds	to	activated	factor	IX	[FIX]	and	factor	X,	present	in	high	con-
centrations	at	sites	of	clot	formation,	and	brings	the	two	molecules	
together,	as	FVIII	does	physiologically.11 Emicizumab has the inher-
ent	properties	of	antibodies	and,	unlike	FVIII,	can	be	administered	






emicizumab	 include	 ease	 of	 administration,	 constant	 hemostatic	
activity,	 and	 the	 possibility	 of	 treating	 patients	 irrespective	 of	 in-
hibitor	presence	with	high	hemostatic	efficacy.	Compared	to	rFVIIa	
or	 FEIBA,	 prophylaxis	 with	 emicizumab	 results	 in	 much	 fewer	
breakthrough	 bleeding	 episodes	 in	 both	 adults	 and	 children	 with	
inhibitors.	 In	 patients	 without	 inhibitors,	 emicizumab	 prophylaxis	
also	leads	to	a	significantly	lower	bleeding	rate	than	previous	FVIII	
prophylaxis.	Emicizumab,	however,	has	some	potential	weaknesses.	
The most important is that the correction of the coagulation defect 
is	only	partial,	which	leaves	the	patients	treated	with	emicizumab	at	
risk	of	bleeding	complications	 in	certain	situations	such	as	 trauma	
or invasive procedures.7 Emicizumab cannot therefore be consid-






agents. Other disadvantages include the difficulty in assessing and 




3  |  REMODELING OF TRE ATMENT 
MODALITIES TODAY
The treatment and prevention of bleeding complications in patients 
with	FVIII	inhibitors	are	typically	based	on	two	conventional	bypassing	
agents:	rFVIIa	and/or	FEIBA.	Like	FVIII,	these	agents	must	be	admin-
istered	 intravenously	 and	have	 a	 short	 half-	life,	 two	major	 obstacles	
against their prophylactic use. It is therefore not surprising that emi-
cizumab	has	emerged	as	an	at	 least	as	effective	alternative	to	rFVIIa	
and	FEIBA.	Emicizumab	 is	 recommended	for	patients	with	persistent	
inhibitors,	with	or	without	 prior	 attempts	 at	 eradication	 through	 im-
mune	tolerance	 induction	 (ITI);	 it	 is	currently	being	studied	as	a	pre-
ventive bypass agent during ITI.13	Emicizumab	is	able	to	replace	FVIII	
concentrate for prophylactic use in patients with severe hemophilia 
A	without	inhibitors.14 The potential for use in this indication is enor-




patients by providing them with a less burdensome treatment option 
associated	with	 nonfluctuant	 coagulation	 status.	 Finally,	 emicizumab	
offers	the	prospect	of	starting	preventive	treatment	early	 in	 life,	well	
before	any	hemorrhagic	event	in	newborns	with	severe	hemophilia	A,	
an option that is currently being validated.15	Although	the	modalities	of	
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4  |  MUTATION IN HEMOPHILIA 
TRE ATMENT AND FUTURE C ARE
The	rapid	and	large-	scale	use	of	emicizumab	could	in	the	near	future	
have	major	consequences	 for	 the	management	of	hemophilia,	 some	
of	them,	although	hypothetical,	negative	or	possibly	disastrous.	Very	
young children treated early with emicizumab could grow up without 
developing or recognizing the symptoms of hemarthrosis and without 
acquiring	the	skills	necessary	for	intravenous	administration	of	concen-
trate. The delay in obtaining intravenous treatment could potentially 
lead to more joint damage than in patients able to treat themselves. 
The fact that administration of emicizumab is increasingly started in 
early	childhood,	including	in	patients	<1	year	of	age,	could	mean	that	
inhibitors	after	a	FVIII	exposure	may	appear	at	a	much	later	age	and	
can go undetected because emicizumab is effective in patients with 
inhibitors.	However,	if	these	patients	develop	an	inhibitor	and	require	
an	invasive	procedure	or	urgent	surgery,	the	lack	of	knowledge	of	the	
presence	of	 an	 inhibitor	 could	be	disastrous.	The	 lack	of	 laboratory	
monitoring of emicizumab means that some laboratory facilities are 
likely	to	downgrade	their	hemophilia	sections.	The	limited	availability	
of highly specialized tests such as chromogenic assays using bovine 
FVIII	reagents17 could impact the care of patients with hemophilia in 
emergency	 situations	 in	many	 places.	 Some	 patients	may	 not	want	
to	visit	hemophilia	treatment	centers	(HTCs),	and	this	is	all	the	more	
problematic when one considers countries that do not have a nation-
alized	system,	such	as	the	United	States.	Telemedicine	could	alleviate	
this	problem,	but	the	need	for	blood	monitoring	will	always	be	there.
5  |  SHIF T IN R ATE OF ADOPTION
With unusual speed and stimulated by promising results of clini-
cal	studies	and	a	variety	of	consensus	and	expert	opinions,13,18-	20 
emicizumab has rapidly replaced conventional bypassing agents 
for patients with inhibitors and is recognized as the prophylactic 






is increasingly emerging as a major or even leading therapeutic 






be	 self-	administered	 by	 noncandidates	 for	 regular	 intravenous	
infusions	of	bypassing	agents	or	FVIII	 concentrates,	 emicizumab	
increases	the	number	of	patients	on	prophylaxis	with	no	market-
ing	 competition.	 There	 are	 currently	 no	 peer-	reviewed	 or	 freely	
accessible data21 available on the impact of emicizumab on the 
market	shares	of	the	different	treatment	options	for	hemophilia	A	
in countries where emicizumab is reimbursed in both indications.
Although	the	hemophilia	community	has	seen	many	innovations	in	
recent	decades,	few	single	products	have	been	adopted	as	quickly	or	as	
widely. This is all the more important when one considers that there is 
currently no alternative approved product with the same profile. In this 
context,	there	is	a	real	risk	that	emicizumab	could	acquire	a	monopolistic	
position	in	certain	HTCs,	jeopardizing	the	wide	diversity	of	treatments	
previously available with impact on product competition systems.




FVIII	 concentrates	 of	 increasing	 purity,	 multiple	 generations	 of	 re-
combinant	FVIII	ultimately	devoid	of	any	human	or	animal	protein	and	
products	with	extended	half-	life	using	technologies	such	as	Fc	or	al-
bumin fusion and pegylation.10	Emicizumab	marks	a	break	in	this	se-
quence	by	offering	the	first	therapy,	with	a	totally	new	mode	of	action,	
distributed by a single company with no current direct competitor. 
Despite	its	advantages,	therapy	with	emicizumab	remains	dependent	
on	 conventional	 treatments	 (bypass	 and	FVIII	 agents)	 in	 certain	 cir-
cumstances such as trauma and invasive procedures.7	As	of	today,	it	
is difficult to anticipate what the next major innovations in the field of 
hemophilia	will	be,	how	they	will	be	adopted,	and	how	and	whether	




subcutaneous	formulations	of	FVIII.22 It is also difficult to assess the 
impact that emicizumab will have on the further development and 
adoption of gene therapy and nonsubstitutive therapies such as the 
coagulation	rebalancing	agents	in	patients	with	hemophilia	A.
Assuming	 that	 these	 treatment	 options	 are	 successfully	 de-
veloped,	 it	 is	 highly	 unlikely	 that	 they	will	modify	 the	 hemophilia	





thrombotic	 risks,	 it	 is	 unlikely	 that	 coagulation	 rebalancing	 agents	
will	largely	replace	FVIII	and	FIX	concentrates.	As	for	gene	therapy,	
it seems increasingly attractive for severe hemophilia B but its dis-
ruptive	impact	should	be	limited,	at	least	in	the	near	future.
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FVIII,	 have	 gradually	 been	 replaced	 by	 international	 companies.	
These	companies	have	specialized	in	the	large-	scale	collection	and	
fractionation	of	plasma	and	the	production	of	plasma-	derived	FVIII	
concentrates distributed in several countries. The development of 
recombinant	 FVIII	 was	 initiated	 by	 companies	 already	 involved	 in	
the	production	of	plasma-	derived	concentrates	or	who	were	com-
pletely new to the field of hemophilia therapy. There is no other rare 





of new players that are challenging the supremacy of some histori-
cal pharmaceutical leaders. The success of emicizumab could totally 





A	 striking	example	of	 this	worrying	development	 is	 the	 recent	
interruption	in	the	production	of	a	plasma-	derived	FIX	concentrate	
(Mononine,	 CSL	 Behring,	 Marburg,	 Germany),	 which	 did	 not	 sur-
vive	the	success	of	EHL-	FIX.23 This decision exposes many patients 
worldwide	to	the	risk	of	not	having	access	to	a	treatment	that	is	cer-
tainly	less	sophisticated	and	more	burdensome	but	equally	effective	
in terms of bleeding control.




created an environment highly beneficial to hemophilia treatment. 
Educational initiatives have never been as prominent in the form of 
congresses,	symposia,	preceptorships,	and	multiple	other	activities.	
These	have	made	a	significant	contribution	to	improving	knowledge	
and	 multidisciplinary	 care	 of	 hemophilia,	 a	 discipline	 that	 is	 little	
taught in medical schools and in the curricula of future hematology 
specialists.	 Furthermore,	 this	 stimulating	 landscape	has	motivated	
the pharmaceutical companies to try and stand out and position 
themselves.	This	 is	how	joint	ultrasound,24 personalized treatment 
with	 pharmacokinetic	 tools,25 and the management of comorbidi-
ties in older patients26 were brought to the forefront and aroused 
unprecedented	 interest.	 In	 addition,	 scientific	 societies,	 patients’	
associations,	 lay	 hemophilia	 organizations,	 and	 many	 HTCs	 have	
benefited	from	the	financial	support	of	pharmaceutical	companies,	
a support that is sometimes critical and whose loss could jeopard-
ize	the	sustainability	of	certain	structures.	Ideally,	all	these	organi-
zations	should	function	without	 industry	support,	but	 this	 is	quite	
difficult	to	achieve	in	the	field	of	rare	diseases.	Clearly,	the	quickly	
changing	hemophilia	therapeutic	landscape	will	have	consequences	
on many of the initiatives described above. This impact is difficult 
to	assess,	but	 the	possible	 repercussions	of	a	 redistribution	of	 re-
sources in the field of hemophilia should be anticipated.
9  |  NE W CHALLENGES IN ACCESS TO 
C ARE GLOBALLY
On	 a	 global	 scale,	 hemophilia	 treatments	 are	 currently	 accessible	





sons with hemophilia residing in the most developed countries have 
routine access to standard treatments and innovations. In these coun-
tries,	treatments	are	largely	or	totally	reimbursed	by	effective	social	
security	and	solidarity	systems.	Worldwide,	the	majority	of	persons	
with hemophilia either have no access to treatment or have access 
to	very	 limited	quantities,	often	obtained	through	humanitarian	do-
nation programs.28 These programs have experienced tremendous 
growth	in	recent	years,	stimulated	by	the	dynamism	of	the	WFH	and	




cess	 to	 a	 wide	 range	 of	 increasingly	 ambitious	 treatment	 options,	




constantly improving in both worlds. The revolution of the therapeu-
tic landscape in the developed world should not be at the expense 
of the less developed countries. Emicizumab is indeed ideally suited 
for	long-	duration	subcutaneous	treatment	of	patients	in	low-	income	
countries who do not receive training for intravenous injections and 
live	great	distances	away	from	HTCs.	To	make	this	ambition	a	reality,	it	
was	announced	in	2019	by	the	WFH	that	prophylactic	treatment	with	
emicizumab would be provided by the Roche Company to as many 
as	1000	people	with	hemophilia	A	in	developing	countries	over	the	
course of 5 years.30 It is hoped that emicizumab will become increas-
ingly	accessible	and	that	the	global	FVIII	production	capacity	will	ben-
efit	less	developed	countries,	a	totally	hypothetical	scenario	today.
10  |  CONCLUSIONS AND PERSPEC TIVES
Emicizumab is currently the first and only approved disruptive treat-
ment	option	 for	hemophilia	A.	Other	disruptive	 treatments	are	ex-
pected	to	follow,	such	as	agents	that	rebalance	coagulation	and	gene	
therapy with the ambition of curing hemophilia.31 While these treat-
ment	 options	 represent	major	 achievements	 or	 expectations,	 their	
adoption and implementation should consider their multiple direct 
or	indirect,	immediate	or	delayed,	consequences	on	hemophilia	care.	
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Divestment	in	hemophilia,	deterioration	in	the	quality	of	multidisci-
plinary	 care	 provided	 by	HTCs,	 trivialization	 of	 hemophilia,	 loss	 of	
expertise,	ignorance	of	certain	possible	complications	in	the	future,	
and regression of donations and education programs are just some 
of the potential side effects that must be anticipated and proactively 
avoided.	As	long	as	treatments	that	cure	all	patients	with	hemophilia	
worldwide	are	not	available,	it	seems	important	to	remain	vigilant	and	
preserve everything that contributes to giving all patients the best 
possible care.
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